TAP1-TAP2 heterodimeric complexes are recognized as the transporter associated with antigen processing of major histocompatibility complex class I peptides for recognition by tumor-specific cytotoxic T lymphocytes. In this study, we investigated the immunohistochemical expression of TAP1 and TAP2 in 160 patients with breast cancer and correlated their expression levels with clinicopathologic parameters. The median age of the patient cohort was 52.5 years (range, 30-86 years). Both TAP1 and TAP2 immunohistochemical expression levels correlated significantly with breast cancer characteristics (P < .001). TAP1 expression levels were low to negative in stage I breast tumors. TAP1 and TAP2 levels were significantly higher in grade 3 tumors than low-grade (grade 1 and 2) tumors. TAP1 and TAP2 expression levels were not significantly different among different levels of HER2-expressing tumors and did not vary by estrogen and progesterone receptor status or patient age. Both TAP1 and TAP2 overexpression in breast cancer might be an indicator of an aggressive breast tumor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706630 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0187323 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Novel Inherited N-terminus TAP1 Variants and Severe Clinical Manifestations- Are Genotype-Phenotype Correlations Emerging?
J Clin Immunol
January 2025
Division of Allergy and Immunology, Children's Hospital of Philadelphia, Philadelphia, 19104, USA.
Major histocompatibility complex class I deficiency results from deleterious biallelic variants in TAP1, TAP2, TAPBP, and B2M genes. Only a few patients with variant-curated TAP1 deficiency (TAP1D) have been reported in the literature and the clinical phenotype has been variable with an emphasis on autoimmune and inflammatory complications. We report TAP1D in a Nepalese girl with a severe clinical phenotype with serious viral infections at a very young age.
View Article and Find Full Text PDFpUS6 in pseudorabies virus participates in the process of inhibiting antigen presentation by inhibiting the assembly of peptide loading complex.
BMC Vet Res
October 2024
College of Veterinary Medicine, Henan Agricultural University, 450046, Zhengzhou, People's Republic of China.
Article Synopsis
- Pseudorabies virus (PRV) can create lifelong infections in nerve cells and blood lymphocytes, avoiding the immune system and potentially causing fetal death.
- The virus evades immune responses by downregulating swine leukocyte antigen class I (SLA I) molecules, but the specific mechanisms behind this suppression are poorly understood.
- Research shows that PRV proteins pUL44 and pUS6 significantly decrease SLA I expression, with pUS6 also affecting transport proteins that help present antigens, highlighting how PRV can hinder immune detection.
Type I bare lymphocyte syndrome with novel TAP1 and TAP2 pathogenic variants.
JAAD Case Rep
September 2024
Division of Dermatology, Department of Medicine, King Abdulaziz Medical City, Jeddah, Saudi Arabia.
Determination of the Immunomodulatory Role of OTOP2 in Colon Adenocarcinoma.
J Cancer
July 2024
Department of Pathology, National Clinical Research Centre for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Centre for Cancer, Tianjin Medical University Cancer Institute and Hospital, Huanhu West Road, Hexi District, Tianjin 300060, China.
Article Synopsis
- Otopetrin 2 (OTOP2) is a crucial ion channel protein involved in cell signaling and development, with its tumor-suppressing role highlighted in colon adenocarcinoma (COAD) studies.
- * OTOP2 expression was found to be significantly decreased in COAD patients, and higher levels of OTOP2 were linked to better survival outcomes and immune responses.
- * The research suggests that OTOP2 may serve as a valuable prognostic marker and predictor of immunotherapy effectiveness for patients with COAD.
Phenotypic and pathomechanistic overlap between tapasin and TAP deficiencies.
J Allergy Clin Immunol
October 2024
Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany; Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany. Electronic address:
Article Synopsis
- Human tapasin deficiency leads to a significant reduction in MHC-I expression on the cell surface, which is linked to immune system issues and increased susceptibility to infections like herpes zoster.
- A novel genetic variant in the TAPBP gene was found in a patient, resulting in this deficiency, and laboratory tests showed the deficiency affects both the transport proteins (TAP1 and TAP2) and MHC-I trafficking to the membrane.
- Treatment with IFN-α was shown to enhance MHC-I expression on the surface of affected cells, providing a possible therapeutic direction for those with tapasin deficiency.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!